編號
R3-005
徵稿主題
Clinical Trial / Chemotherapy / Targeted Therapy / Immunotherapy / Cell Therapy
題目
Durvalumab合併Gemcitabine/Cisplatin於混合型肝膽管癌（cHCC-CCA）與膽管癌（CCA）之療效與安全性比較
作者群
許宇維1,2,
張境夫2,3,
吳教恩2,4,
葉光揚2,5,
徐潤德2,6,
陳仁熙1,2,7,
周文其1,2,7
服務單位
1 Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
2 College of Medicine, Chang Gung University, Taoyuan, Taiwan
3 Department of Hematology and Oncology, Chang Gung Memorial Hospital at Taoyuan, Taoyuan, Taiwan
4 Department of Hematology and Oncology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan
5 Department of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan
6 Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
7 Department of Hematology and Oncology, Chang Gung Memorial Hospital at Taipei, Taipei, Taiwan
